However, ROCK inhibitors have not yet been accepted for treating metabolic disorders due to potential systemic side effects, including hypotension caused by smooth muscle relaxation due to both ROCK1 and ROCK2 are similarly inhibited (54–56, 191). This evidence concerns the gene ROCK1 and Other metabolic disease.